| Submission | Oct. 01, 2024 |
| Submission [Line Items] | |
| Central Index Key | 0001815442 |
| Registrant Name | Kymera Therapeutics, Inc. |
| Form Type | S-3 |
| Submission Type | S-3ASR |
| Fee Exhibit Type | EX-FILING FEES |
| Offerings | Oct. 01, 2024 USD ($) shares |
| Offering: 1 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Common Stock, $0.0001 par value |
| Offering Note | (1) Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be. (2) The amount to be registered consists of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of debt securities, common stock, preferred stock or units as may be issued upon exercise of warrants registered hereby, as the case may be, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon exercise, settlement, exchange or conversion of other securities. (3) The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security. |
| Offering: 2 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Preferred Stock, $0.0001 par value |
| Offering Note | (4) Including such indeterminate amount of preferred stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be. (5) See Note 2. (6) See Note 3. |
| Offering: 3 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Debt Securities |
| Offering Note | (7) Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be. (8) See Note 2. (9) See Note 3. |
| Offering: 4 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Other |
| Security Class Title | Warrants |
| Offering Note | (10) Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock, preferred stock, debt securities, or units registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required. (11) See Note 2. (12) See Note 3. |
| Offering: 5 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Other |
| Security Class Title | Units |
| Offering Note | (13) Each unit will be issued under a unit agreement and will represent an interest in two or more securities registered pursuant to this registration statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required. (14) See Note 2. (15) See Note 3. |
| Offering: 6 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(o) | true |
| Security Type | Equity |
| Security Class Title | Common Stock, $0.0001 par value |
| Amount Registered | shares | 300,000,000 |
| Proposed Maximum Offering Price per Unit | 0 |
| Maximum Aggregate Offering Price | $ 300,000,000 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 45,930 |
| Offering Note | (16) In accordance with Rules 456(b) and 457(r) under the Securities Act, except with respect to the $45,930.00 to be paid in connection with the primary offering of common stock described in the table, which is being paid with the filing of this registration statement, the registrant is deferring payment of all registration fees and will pay the registration fees subsequently in advance or on a “pay-as-you-go” |
| Offsets | Oct. 01, 2024 USD ($) |
| Offset: 1 | |
| Offset Payment: | |
| Offset Claimed | true |
| Rule 457(p) Offset | true |
| Registrant or Filer Name | Kymera Therapeutics, Inc. |
| Form or Filing Type | S-3 |
| File Number | 333-259955 |
| Initial Filing Date | Oct. 01, 2021 |
| Fee Offset Claimed | $ 18,540.92 |
| Security Type Associated with Fee Offset Claimed | Equity |
| Security Title Associated with Fee Offset Claimed | Common Stock |
| Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | $ 200,009,936.3 |
| Offset Note | (1) On October 1, 2021, the registrant filed a registration statement on Form S-3 No. 333-254236) “at-the-market” |
| Termination / Withdrawal Statement | As of the termination of the offering made pursuant to the 2021 ATM Prospectus, which occurred on October 1, 2024 when the Prior Registration Statement expired, $200,009,936.30 of shares of the registrant’s common stock remained unsold. Pursuant to Rule 457(p) under the Securities Act, filing fees in the amount of $18,540.92 relating to the unsold securities are being carried forward. |
| Offset: 2 | |
| Offset Payment: | |
| Offset Claimed | false |
| Rule 457(p) Offset | true |
| Registrant or Filer Name | Kymera Therapeutics, Inc. |
| Form or Filing Type | S-3 |
| File Number | 333-259955 |
| Filing Date | Oct. 01, 2021 |
| Fee Paid with Fee Offset Source | $ 18,540.92 |
| Termination / Withdrawal Statement | As of the termination of the offering made pursuant to the 2021 ATM Prospectus, which occurred on October 1, 2024 when the Prior Registration Statement expired, $200,009,936.30 of shares of the registrant’s common stock remained unsold. Pursuant to Rule 457(p) under the Securities Act, filing fees in the amount of $18,540.92 relating to the unsold securities are being carried forward. |
| Fees Summary | Oct. 01, 2024 USD ($) |
| Fees Summary [Line Items] | |
| Total Offering | $ 300,000,000 |
| Previously Paid Amount | 0 |
| Total Fee Amount | 45,930 |
| Total Offset Amount | 18,540.92 |
| Net Fee | $ 27,389.08 |
